Navigation Links
Light activated anticancer drug targeted to DNA using cisplatin like sub-units

One of the most effective chemotherapy drugs against cancer is cisplatin because it attaches to cancer DNA and disrupts repair. However, it also kills healthy tissue. Many scientists are creating alternative drugs or cisplatin analogs in attempts to find treatments without side effects. One approach to analog development is light activated drugs, or photodynamic therapy (PDT). Now a Virginia Tech chemistry-biology research team that has been working on both non-cisplatin drugs and cisplatin analogs has combined their findings to create a molecular complex (supramolecule) that exploits cisplatins tumor targeting to deliver a light activated drug.

The latest results from the group's research to create a DNA targeting, light activated anticancer drug will be presented at the 231st American Chemical Society national meeting in Atlanta on March 26-30.

Chemistry professor Karen J. Brewer reports that the group has developed supramolecular complexes that combine light-absorbing PDT agents and cisplatin like units. Previous anticancer molecules created by the group have contained platinum-based molecules that bind DNA. They have also developed new light activated systems able to photocleave DNA. This report combines these two approaches to target the drug to DNA using cisplatin like units, directing the light activation to tumor cells and the sub-cellular target, DNA.

"In the past, our light activated systems had to find the DNA within the cell, an often inefficient process. Now we have added the DNA targeting drug," Brewer said. "We were working on cisplatin analogs before, so we have tied it to light activated systems."

Cisplatin begins its interaction with cancer DNA by binding to the nitrogen atoms of the DNA bases, typically guanine. Our new supramolecules use this nitrogen-binding site to hold the light activated drug at the target until signaled to activate. Thus the new supramolecules can be delivered to the tumor site but remain ine
'"/>

Source:Virginia Tech


Page: 1 2

Related biology news :

1. Light therapy may combat fungal infections, new evidence suggests
2. New Research Shows Artificial Light at Night Stimulates Breast Cancer Growth in Laboratory Mice
3. Light guides flight of migratory birds
4. Light-sensitive photoswitches could restore sight to those with macular degeneration
5. Light wine intake is associated with longer life expectancy in men
6. Light-based probe sees early cancers in first tests on human tissue
7. Lighting up life: Cold Spring Harbor Protocols presents tips for creating glowing plants
8. T cells activated to fight HIV basis for dendritic cell therapeutic vaccine
9. Reactivated gene shrinks tumors
10. New drug shows promise as powerful anticancer agent
11. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
Post Your Comments:
(Date:6/24/2015)... The biologics safety testing market is growing ... market include growth of the pharmaceutical and biological industries ... the years, the number of drug approvals in North ... FDA approved 225 drug applications and Health Canada approved ... accounted for 3,822 of the pharmaceutical and ...
(Date:6/24/2015)... Switzerland , June 24, 2015 ... partnership with emerging biometric password solution one face ... one face in, entering ... a ground-breaking and affordable multifactor-authentication biometric answer to ... recognition technology, provided in partnership with KeyLemon, one ...
(Date:6/23/2015)... PALM BEACH GARDENS, Fla. , June ... of multi-factor identity management and authentication solutions, today ... Altus strong, multi-factor authentication solution.  The ... ease of use of the DigitalPersona Altus ... and biometric reader compatibility. In ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... 9 CBS Vision, the research division of CBS Corporation, and ... new research partnership that will allow OMD,s clients access to the ... in Las Vegas. , The new venture, which marries the ... will be called Communications Lab@OMD . , CBS,s Television City ...
... Spring Harbor, N.Y. Oncologists have had their hands ... have mutations that disable a protein called p53. As ... within cells. When cells lose p53, tumors grow aggressively ... might be tough, but they,re not invincible, suggests a ...
... The brilliance of butterfly wings has inspired a ... in the fields of security, energy and the environment. ... have just signed a collaborative contract to develop new ... Over the next three years a team of physicists ...
Cached Biology News:CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 2CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 3CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 4CSHL study shows that some malignant tumors can be shut down after all 2CSHL study shows that some malignant tumors can be shut down after all 3£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2
(Date:6/30/2015)... ... June 30, 2015 , ... ... a webinar to provide advanced scientific research into new classes of Nanoscale Graphene-based ... energy. Touted as 'the wonder material of the 21st Century' by the ...
(Date:6/30/2015)... ... June 30, 2015 , ... With ... not sacrifice selectivity to achieve faster flow rates in comparison to nylon or ... significant open space to allow easy liquid flow while trapping particulates as small ...
(Date:6/30/2015)... N.Y. , June 30, 2015  Custom Computer ... announced today that they are silver sponsors of the ... official PCDC sponsor, Custom is lending their support of ... low-income communities. Since its founding in 1993, ... the primary care area.  PCDC has financed over 100 ...
(Date:6/30/2015)... Florida (PRWEB) , ... June 30, 2015 , ... ... cannabis digital media company, launched “Cannavoices,” an unprecedented digital video and broadcast ... largest but also the most dynamic collection of legal medical cannabis stories ever ...
Breaking Biology Technology:How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4New Nanofiber Membrane Provides Fast, Efficient Filtration 2Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3
... ViroPharma Incorporated (Nasdaq: VPHM ) ... transaction, $45 million principal amount or 18 percent ... 2017 for total consideration of approximately $21.2 million. ... million of principal debt are outstanding.As a result ...
... Patient Safety & Satisfaction Record ChallengeCORONA DEL MAR, ... Anesthesiologists (ASA) functions much like the American Medical ... Anesthesiology and JAMA , respectively) and ... Nonetheless, both groups function primarily (and legitimately) as ...
... 24, 2009, at 6:00 PM Central European Time/1:00 PM Eastern Time/10:00 ... MTA: CTIC) management team will host a Special Meeting in lieu ... at 501 Elliott Ave. West, Seattle, WA 98119. The meeting will ... archived for replay., ...
Cached Biology Technology:ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes 2ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes 3ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes 4American Society of Anesthesiologists Primary Agenda Displayed Says Dr. Barry Friedberg of Cosmetic Surgery Anesthesia 2Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009 2
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
... GenBank Accession Number : NM_002542 Immunogen ... corresponding to residues 166-223 of human AP-2α ... 0.1M Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% ... to 30% Quality Assurance: routinely evaluated by ...
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
Biology Products: